
CLAIMS:


1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2302), or a salt thereof.

2. The modified oligonucleotide of claim 1, which is the sodium salt, the potassium salt, or a combination thereof.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 2302).

4. An oligomeric compound comprising a modified oligonucleotide according to the following chemical notation:

Ges Teo Geo Teo ^{m}Ceo Aeo Tds Ads Ads Tds Tds Tds Tds ^{m}Cds Tds Tds Aeo Ges ^{m}Ces Te (SEQ ID NO: 2302), wherein:

A = an adenine nucleobase,

^{m}C = a 5-methylcytosine nucleobase,

G = a guanine nucleobase,

T = a thymine nucleobase,

e = a 2'-$O(CH_2)_2OCH_3$ ribosyl sugar moiety,

d = a 2’-β-D-deoxyribosyl sugar moiety

s = a phosphorothioate internucleoside linkage, and

o = a phosphodiester internucleoside linkage.

5. An oligomeric compound of claim 4 comprising a conjugate group.

6. A population of modified oligonucleotides of any of claims 1-3 or a population of oligomeric compounds of claim 4 or claim 5, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

7. A pharmaceutical composition comprising a modified oligonucleotide of any of claims 1-3, an oligomeric compound of claim 4 or claim 5, or a population of modified oligonucleotides or oligomeric compounds of claim 6, and a pharmaceutically acceptable diluent.

8. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable diluent is artificial cerebrospinal fluid.

9. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable diluent is phosphate-buffered saline (PBS).

10. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition consists of the modified oligonucleotide or oligomeric compound and artificial cerebrospinal fluid.

11. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition consists of the modified oligonucleotide or oligomeric compound and PBS.

12. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition consists of the population of modified oligonucleotides or oligomeric compounds and artificial cerebrospinal fluid.

13. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition consists of the population of modified oligonucleotides or oligomeric compounds and PBS.